AVIR Stock Summary and Trading Ideas (Atea Pharmaceuticals | NASDAQ:AVIR)

Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).

Atea Pharmaceuticals trades on the NASDAQ stock market under the symbol AVIR.

As of January 15, 2026, AVIR stock price declined to $3.51 with 314,479 million shares trading.

AVIR has a beta of 0.49, meaning it tends to be less sensitive to market movements. AVIR has a correlation of 0.04 to the broad based SPY ETF.

AVIR has a market cap of $274.23 million. This is considered a Small Cap stock.

In the last 3 years, AVIR traded as high as $5.19 and as low as $2.46.

The top ETF exchange traded funds that AVIR belongs to (by Net Assets): VTI, IWM, VXF, IWN, IBB.

AVIR has underperformed the market in the last year with a price return of +11.4% while the SPY ETF gained +20.4%. However, in the short term, AVIR had mixed performance relative to the market. It has outperformed in the last 3 months, returning +11.8% vs +5.0% return in SPY. But in the last 2 weeks, AVIR shares have been beat by the market, returning -1.7% compared to an SPY return of +1.7%.

AVIR support price is $3.42 and resistance is $3.66 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AVIR shares will trade within this expected range on the day.